Return to homepagePandemic Pact

Genome-wide CRISPR screens to identify new therapeutic targets and inhibit SARS-CoV-2 replication

Grant number: Unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    ANR

  • Principal Investigator

    Caroline GOUJON

  • Research Location

    France

  • Lead Research Institution

    Institut de Recherche en Infectiologie de Montpellier (IRIM) ? CNRS

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The CRISPR-TARGET-CoV project, coordinated by Caroline Goujou (UMR 9004 Institut de Recherche en Infectiologie de Montpellier (IRIM) - CNRS), aims to produce screens using CRISPR technology at the genome scale in order to identify cofactors and cellular SARS-CoV-2 inhibitors. He will then focus on screening molecules of interest selected for their relevance to the cellular factors identified. The effect of the best molecules will be validated ex vivo in a 3D system of primary respiratory targets of SARS-CoV-2.